The Association of CYP2D6 Genotype and Postoperative Nausea and Vomiting in Orthopedic Trauma Patients

Biological Research for Nursing

Volumn 15, Issue 4, 2013, Pages 382-389

  Wesmiller, Susan W ^a   Henker, Richard A ^a   Sereika, Susan M ^a   Donovan, Heidi S ^a   Meng, Li ^b   Gruen, Gary S ^b   Tarkin, Ivan S ^b   Conley, Yvette P ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2D6; nausea; PONV; postoperative symptoms; vomiting

Indexed keywords

ANTIEMETIC AGENT; CYTOCHROME P450 2D6; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; FRACTURE; GENETICS; GENOTYPE; HUMAN; INJURY; LIMB; MALE; METABOLISM; MIDDLE AGED; NAUSEA; ORTHOPEDIC SURGERY; PHENOTYPE; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PAIN; POSTOPERATIVE SYMPTOMS; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SALIVA; VOMITING; YOUNG ADULT;

CYP2D6; NAUSEA; PONV; POSTOPERATIVE SYMPTOMS; VOMITING;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; ANTIEMETICS; CYTOCHROME P-450 CYP2D6; EXTREMITIES; FEMALE; FRACTURES, BONE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; PAIN, POSTOPERATIVE; PHENOTYPE; POSTOPERATIVE NAUSEA AND VOMITING; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; SALIVA; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 84884138204     PISSN: 10998004     EISSN: 15524175     Source Type: Journal    
DOI: 10.1177/1099800412449181     Document Type: Article

References (46)

1. ASPAN's evidence-based clinical practice guideline for the prevention and/or management of PONV/PDNV.Journal of PeriAnesthesia Nursing. 2006;71:230-250.
2. Apfel C.,Greim C.,Habuitz I.,Goepfert C.,Usadel J.,Sefrin P.,Roewer N.A risk score to predict the probability of postoperative vomiting in adults.Acta Anaesthesiologica Scandinavica. 2008;42:495-501.
3. Apfel C.,Laara E.,Koivuranta M.,Greim C.,Roewer N.A simplified risk score for predicting PONV: Conclusions from cross-validations between two centers.Anesthesiology. 1999;91:693-700.
4. Arneth B.,Shams M.,Hiemke C.,Hartter S.Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, and/or duplication of the CYP2D6 gene.Clinical Biochemistry. 2009;42:1282-1290.
5. Brattwall M.,Stomberg M.,Rawal N.,Segerdahl, Houltz E.,Jakobbson J.Postoperative impact of regular tobacco use, smoking or snuffing, a prospective multi-center study.Acta Anaesthesiologica Scandinavica. 2009;10:1-7.
6. Candiotti K. A.,Birnbach D. J.,Lubarsky D. A.,Nhuch F.,Kamat A., Andrews D.The impact of pharmacogenomics on postoperative nausea and vomiting: Do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis?.Anesthesiology. 2005;102:543-549.
7. Chou W.,Wang C.,Liu P.,Liu C.,Tseng C.,Jawan B.Human opioid receptor A188G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy.Anesthesiology. 2006;105:334-337.
8. CorkR.IsaacI.ElsharydahA.SaleemiS.ZaviscaF.AlexanderL. (2004). A comparison of the verbal rating scale and the visual analog scale for pain assessment. Internet Journal of Anesthesiology, 8.Retrieved March 21, 2010, fromhttp://www.ispub.com/ostia/index.php?xmlFilePath=journals/ija/vol8n1/vrs.xml.
9. Daly A.,Brockmöller J.,Broly F.,Eichelbaum M.,Evans W.,Gonzalez F,Zanger U. M.Nomenclature for human CYP2D6 alleles.Pharmacogenetics. 1996;6:193-201.
10. de Leon J.,Armstrong S. C.,Cozza K.Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19.Psyschosomatics. 2006;47:75-85.
11. Eichelbaum M.,Spannbrucker N.,Steincke B.,Dengler H.Defective N-oxidation of sparteine in man: A new pharmacogenetic defect.European Journal of Clinical Pharmacology. 1979;16:183-187.
12. Furman K. D.,Grimm D. R.,Mueller T.,Hollery-Shanks R. R.,Bertz R. J.,Williams L. A.,Katz D. A.Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics.Pharmacogenetics. 2004;14:279-284.
13. Gaedigk A.,Simon S.,Pearce R.,Bradford L.,Kennedy M.,Leeder J.The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype.Clinical Pharmacology and Therapeutics. 2008;83:234-242.
14. Ho K.,Gan T.Pharmacology, pharmacogenetics and clinical efficacy of 5HT3 receptor antagonists for postoperative nausea and vomiting.Current Opinions in Anaesthesiology. 2006;19:606-611.
15. Holmquist G.Opioid metabolism and effects of cytochrome P450.Pain Medicine. 2009;10:S20-S29.
16. Ingelman-SundbergM.DalyA.NebertD. (2009). Home page of Human Cytochrome P450(CYP) Allele Nomenclature Committee. Retrieved from NCBI website athttp://www.cypalleles.ki.se/cyp2d6.htm.
17. Janicki P.,Schuler H.,Jarzembowski T.,Rossi M.Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype.Anesthesia & Analgesia. 2006;102:1127-1133.
18. Jolley S.Managing post-operative nausea and vomiting.Nursing Standards. 2001;15:47-52.
19. Junger A.,Hartmann B.,Benson M.,Schindler E.,Dietrich G.,Jost A.,Hempelmannn G.The use of an anesthesia information management system for prediction of antiemetic rescue treatment at the postanesthesia care unit.Anesthesia & Analgesia. 2001;92:1203-1209.
20. Kaiser R.,Sezer O.,Papies A.,Bauer S.,Schelenz C.,Tremblay P.,Brockmöller J.Patient-tailored anti-emetic treatment with 5HT3 receptor antagonists according to cytochrome P-450 2D6 genotypes.Journal of Clinical Oncology. 2002;20:2805-2811.
21. Kim E.,Choi C.,Kang C.,Bae S.Adverse events in analgesic treatment with tramadol associated with CYP2D6 extensive-metabolizer and OPRM1 high-expression variants.Annals of Rheumatoid Arthritis. 2010;69:1888-1891.
22. Kirchheiner J.,Jan-Tobias H.,Keulen M.,Bauer S.,Roots I.,Brockmöller J.Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.Journal of Clinical Psychopharmacology. 2008;28:78-83.
23. Kranke P.,Roewer N.,Smith A.,Piper S.,Wallenborn J.,Eberhart L.Postoperative nausea and vomiting: What are we waiting for?.Anesthesia Analgesia. 2009;108:706-712.
24. Leppert W.CYP2D6 in the metabolism of opioids for mild to moderate pain.Pharmacology. 2011;87:274-285.
25. Marla S.,Stallard S.Systematic review of day surgery for breast cancer.International Journal of Surgery. 2009;7:318-323.
26. McCaffery M.,Pasero C.Pain: Clinical manual. 1999). Pain: Clinical manual (2nd ed.). St. Louis, MO: Mosby.St. Louis, MO: Mosby; 1999:.
27. Meng L.,Quinlan J.Assessing risk factors for postoperative nausea and vomiting: A retrospective study in patients undergoing retromastoid craniectomy with microvascular decompression of cranial nerves.Journal of Neurosurgical Anesthesiology. 2006;18:235-239.
28. Miaskowski C.A review of the incidence, causes, consequences and management of gastrointestinal effects associated with postoperative opioid administration.Journal of PeriAnesthesia Nursing. 2009;24:222-228.
29. Murphy M.,Hooper V.,Sullivan E.,Clifford T.,Apfel C.Identification of risk factors for postoperative nausea and vomiting in the perianesthesia adult patient.Journal of PeriAnesthesia Nursing. 2006;21:377-384.
30. Nelson T.Postoperative nausea and vomiting: Understanding the enigma.Journal of PeriAnesthesia Nursing. 2002;17:178-189.
31. Nielson M.,Olsen N.Genetic polymorphisms in the cytochrome P450 and efficacy of 5-HT type 3 receptor antagonists for postoperative nausea and vomiting. (2008).British Journal of Anaesthesia. 2008;101:441-445.
32. Owen R.,Sangkuhl K.,Klein T.,Altman R.Cytochrome P450 2D6.Pharmacogenetics and Genomics. 2009;19:559-562.
33. Roger V.,Go S.,Lloyd-Jones M.,Benjamin J.,Berry D.,Borden B,Turner M.Heart disease and stroke statistics-2012 update: A report from the American Heart Association.Circulation. 2012;125:e2-e220.
34. Sachse C.,Brockmöller J.,Bauer S.,Roots I.Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences.American Journal of Human Genetics. 1997;60:284-295.
35. Sia A.,Lim Y.,Lim E.,Goh R.,Law H.,Landau R,Tan E.A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia.Anesthesiology. 2008;109:520-526.
36. Sinclair D.,Chung F.,Mezei G.Can postoperative nausea and vomiting be predicted?.Anesthesiology. 2000;91:109-118.
37. Stamer U.,Rauers N.,Eun-Hae L.,Mubhoff F.,Stuber F.Ondansetron for the treatment of opioid induced nausea and vomiting: Impact of cytochrome polymorphisms.European Journal of Pain. 2009;13:S193.
38. Stamer U. M.,Bayerer B.,Wolf S.,Hoeft A.,Stüber F.Rapid and reliable method for cytochrome P450 2D6 genotyping.Clinical Chemistry. 2002;48:1412-1417.
39. Susce M.,Murray-Carmichael E.,de Leon J.Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2006;30:1356-1358.
40. Sweeney B.Do genes influence outcome from anaesthesia?.British Journal of Anaesthesia. 2003;103:725-727.
41. Watcha M.,White P.Postoperative nausea and vomiting. Its etiology, treatment and prevention.Anesthesiology. 1992;77:162-184.
42. White P.,O'Hara J.,Roberson C.,Wender R.,Candiotti K.The impact of current anti-emetic practices on patient outcomes: A prospective study on high-risk patients.Anesthesia & Analgesia. 2008;107:452-458.
43. Yang Z.,Yang Z.,Ahreart K.,Morris R.,Zhang Y.,Rodriguez Y.,Candiotti K.CYP2D6 poor metabolizer genotype and smoking predict severe postoperative pain in female patients on arrival to the recovery room.Pain Medicine. 2012;13:604-609.
44. Zhou S.Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.Clinical Pharmacokinetics. 2009;48:689-723.
45. Zhou S.Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II.Clinical Pharmacokinetics. 2010;48:761-804.
46. Zwisler S.,Enggaard T.,Noehr-Jensen L.,Pederson R.,Mikkelsen S.,Nielsen F.,Sindrup S.The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism.Basic and Clinical Pharmacology. 2009;104:335-344.